Skip to content

Author

D. Barouch

7 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections

The two parallel Antibody Mediated Prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here we analyzed HIV-1 acquisition in AMP through the Week 104 final study visit. Against viruses considered...

A. deCamp, M. Juraska, Li Li et al. · 0 citations
Oct 2026

Ionizable lipid impact on mRNA vaccine formulation properties and immunogenicity.

The COVID-19 pandemic disrupted global supply chains, causing shortages of critical lipid-based raw materials for mRNA vaccine production. To enhance formulation resilience, we systematically evaluated the impact of five ionizable lipids (ILs) on lipid nanoparticle (LNP) organization, mRNA delivery and immunogenicity....

Shahad K. Alsaiari, B. Dyett, John L. Daristotle et al. · 0 citations
Open access Oct 2026

Epitope Mapping and MHC Restriction of Next-Generation Tuberculosis Vaccine Antigens in Mice

Background/Objectives: Classical major histocompatibility complex (MHC)-restricted T cells play essential roles in tuberculosis (TB) immunity. Characterizing the antigen targets, dominant epitopes, and MHC restriction of protective T-cell responses is important for understanding TB immunity and next-generation TB vacci...

Samuel J. Vidal, Alejandro A. Espinosa Perez, Ganad D. Neka et al. · 0 citations
Open access Sep 2026

Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection.

People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can face non-AIDS complications, partially driven by chronic immune activation. To define immune perturbations during ART-suppressed viral infection, we performed longitudinal single-cell transcriptomic and plasma proteomic analyses of rhesus mac...

Maanasa Kaza, B. Varco-Merth, G. McElfresh et al. · 0 citations
Open access Sep 2026

Tissue Origins and Immune Correlates of Viral Rebound in SIV-Infected Rhesus Macaques Following ART Discontinuation

The majority of persons living with HIV-1 who discontinue antiretroviral therapy (ART) demonstrate viral rebound, but the tissue-level events that lead to rebound viremia remain poorly understood. Here we report the origin, dynamics, and correlates of viral rebound in 16 rhesus macaques (RMs) infected with molecularly...

Irena V. King, Malika Aid, Emek Kose et al. · 0 citations
Open access Aug 2026

Translational insights into manufacturability and stability of broadly neutralizing antibodies for pediatric HIV prevention: lessons from plant-produced CAP256-VRC26.25

Trans translational insights are provided into the engineering challenges associated with scalable production of broadly neutralizing antibodies and key considerations for developing accessible antibody-based interventions for pediatric HIV prevention are highlighted.

T. Tsekoa, Lusisizwe Kwezi, P. Pillay et al. · 0 citations
Open access Jul 2026

Quantitative Analysis of a Novel Systems-predicted Neutralizing Antibody Titer Assay 2305470

The SNAb assay could successfully multiplex hemagglutinin molecules to quantify the predicted neutralization of twelve analytes simultaneously and did not show an overcounting or undercounting of neutralizing antibody titers.

Lindsay R. McManus, Qixin Wang, Kate S. Levine et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.